aTyr Pharma (NASDAQ:LIFE) Stock Passes Above 200-Day Moving Average of $1.54

Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.54 and traded as high as $1.65. aTyr Pharma shares last traded at $1.60, with a volume of 288,049 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Royal Bank of Canada decreased their price objective on shares of aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, March 15th. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of aTyr Pharma in a report on Friday, March 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $23.67.

aTyr Pharma Price Performance

The stock has a market capitalization of $108.70 million, a PE ratio of -1.67 and a beta of 1.25. The company has a quick ratio of 6.27, a current ratio of 6.27 and a debt-to-equity ratio of 0.02. The stock’s 50-day moving average is $1.82 and its 200 day moving average is $1.54.

aTyr Pharma (NASDAQ:LIFE) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). As a group, equities analysts predict that aTyr Pharma, Inc. will post -0.97 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of aTyr Pharma by 5.1% during the 3rd quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock valued at $13,520,000 after buying an additional 413,162 shares during the last quarter. Pale Fire Capital SE lifted its stake in aTyr Pharma by 425.8% in the fourth quarter. Pale Fire Capital SE now owns 293,706 shares of the biotechnology company’s stock valued at $414,000 after acquiring an additional 237,849 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new position in shares of aTyr Pharma during the 1st quarter worth $117,000. Finally, Granite Bay Wealth Management LLC bought a new position in shares of aTyr Pharma during the 4th quarter valued at $25,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.